MediPurpose Supports Diabetes Research Effort.
"MediPurpose is dedicated to improving the quality of life for those living with diabetes. Our SurgiLance safety lancets are used by them for regular glucose testing," says MediPurpose CEO Patrick Yi.
JDRF is the world's largest charitable funder of and advocate for type 1 (juvenile) diabetes research worldwide. Type 1 Diabetes is a disease which strikes children suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Since its inception in 1970, JDRF has raised more than $1.9 billion to fund direct research.
"With the generous support of companies such as MediPurpose, JDRF can continue its mission to discover, develop and deliver therapeutics to improve the lives of people with diabetes," said Marie Davis, executive director of the organization's Metro Saint Louis / Greater Missouri Chapter.
MediPurpose develops, manufactures and markets innovative healthcare solutions valued by its customers. The company is known for introducing quality safety medical devices that protect healthcare professionals from sharps injury. Founded in 1999, the company achieved rapid success with its SurgiLance safety lancet, quickly becoming one of the top leaders in the US safety lancet market and establishing solid distribution channels worldwide.
The SurgiLance safety lancet has found long-term success in all sectors of the healthcare market and has provided more than 500 million consumers with a safe, simple and effective tool for blood testing. MediPurpose currently offers six color-coded lancets, which are used for capillary blood sampling for a range of testing requirements.
MediPurpose maintains offices in the US, Singapore, the UK, France and Spain. As a globally recognized innovator, MediPurpose has developed a menu of services to assist inventors and growing medical device companies successfully design, patent, manufacture and sell their products.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Mar 1, 2008|
|Previous Article:||Gen-Probe Begins United States Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer.|
|Next Article:||Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program.|